With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

For the first time, the smallest control system of vision in mammals has been mapped—a discovery that opens entirely new ...

Soliris contributed $2.58 billion in global revenues to AZ last year, a 14% drop on the prior year, of which just over $1.4 ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the same rare immune diseases as Soliris.

Neuromyelitis optica spectrum disorder (NMOSD) – also known as neuromyelitis optica (NMO) and Devic’s disease – is a rare, ...

US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.

The U.S. Food and Drug Administration (FDA) has approved Amgen’s UPLIZNA as the first and only treatment for adults living ...